Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

And while this was all true for Christchurch youngster Noah Harrington-Ashton, his recent celebrations also marked the ...

The results represent a "historic" moment in cystic fibrosis care. Vertex has announced successful results from two Phase III studies of Trikafta (elexacaftor ...

The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the ...

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, a poster presentation by Sivagurunathan Sutharsan and colleagues from University Medicine Essen, Ruhrlandklinik, ...

Courtney Boccio wasn’t sure what to expect when she started a clinical trial for a new drug aimed at helping people with cystic fibrosis in the spring of 2018. The 25-year-old Huntington woman was ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...